Undervalued Oncology Opportunity

Beyond AML, the company is advancing SLS009, a CDK9 inhibitor, which has shown early efficacy signals. The combination of a promising clinical portfolio, significant cash reserves, and impending trial readouts positions SLS as an undervalued oncology opportunity with substantial upside potential for shareholders.